Acumen Pharmaceuticals (NASDAQ: ABOS) files Form 144 for insider sale

Rhea-AI Filing Summary

Acumen Pharmaceuticals reported a proposed sale of 2,090 common shares via a broker-assisted cashless exercise on 03/06/2026. The filing lists prior open-market sales by Derek Meisner across January–February 2026, including large blocks of 36,911 shares on 01/08/2026 and 15,085 shares on 01/26/2026.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	2090	6729.80	60573425	03/06/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common stock	03/06/2026	Exercise of employee stock options	Acumen Pharmaceuticals, Inc.			2090	03/06/2026	Broker assisted cashless exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/05/2026	4000	7838.00
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/06/2026	10898	21437.56
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/07/2026	11770	23414.63
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/08/2026	36911	67244.23
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/09/2026	5200	9169.00
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/12/2026	8548	14658.02
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/21/2026	2247	4063.33
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/22/2026	1054	1939.36
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/23/2026	5633	10492.83
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/26/2026	15085	45262.48
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/28/2026	2671	8017.29
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common Stock	02/27/2026	9406	28310.82

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Acumen Pharmaceuticals' Form 144 (ABOS) report?

It reports a proposed sale of 2,090 common shares on 03/06/2026. The method listed is a broker-assisted cashless exercise. The filing also lists multiple earlier open-market sales by Derek Meisner in January–February 2026.

Who is the selling party named in the ABOS Form 144?

The filing identifies Derek Meisner as the selling party for recent transactions. Multiple sales by Mr. Meisner are listed between 01/05/2026 and 02/27/2026, with individual sale sizes shown in the table.

What method is used for the 03/06/2026 transaction in the ABOS filing?

The 03/06/2026 entry is an exercise of employee stock options via a broker-assisted cashless exercise. The filing explicitly states this method alongside the 2,090-share quantity for that date.

Does the Form 144 list prior sales and their sizes for ABOS insiders?

Yes. The filing lists multiple prior sales with dates and share counts. Examples include 36,911 shares on 01/08/2026 and 15,085 shares on 01/26/2026; each sale row shows the date and the number of shares sold.